US 11,708,370 B2
Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
Pasit Phiasivongsa, Hillsborough, CA (US); Katherine Chu, San Francisco, CA (US); Jiang Zhu, San Ramon, CA (US); Kolbot By, San Ramon, CA (US); and Mohammad Reza Masjedizadeh, San Jose, CA (US)
Assigned to Principia Biopharma Inc., Bridgewater, NJ (US)
Filed by Principia Biopharma Inc., South San Francisco, CA (US)
Filed on Dec. 17, 2020, as Appl. No. 17/125,384.
Claims priority of provisional application 62/951,958, filed on Dec. 20, 2019.
Claims priority of provisional application 63/122,309, filed on Dec. 7, 2020.
Prior Publication US 2021/0198264 A1, Jul. 1, 2021
Int. Cl. A61K 31/519 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) 16 Claims
 
1. A solid form of Compound (I):

OG Complex Work Unit Chemistry
wherein the solid form is characterized by a mean bulk density greater than 0.3 g/cc.
 
9. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the solid form according to claim 1.